BN Business News
会社を追加 →
この記事の翻訳を準備しています。それまでの間、英語の原文を表示します。

ビジネス · 1994/9/211 分で読めます

New Drug Applications; Refusal to File; Change in Schedule of Meetings of the Review Committee

ローカル自動翻訳 · 情報源の原言語

概要

The Food and Drug Administration (FDA) is announcing a change in the procedure that the Center for Drug Evaluation and Research (CDER) uses to review its use of its refusal to file (RTF) procedure, by which it refuses to file new drug applications (NDA's) that are facially deficient under FDA's regulations. Since January 1994, the committee has been meeting bi-monthly rather than quarterly. Because the committee will review all RTF decisions rather than only a few, new drug application (NDA) applicants will not need to submit requests for review.

情報源の原言語: Federal Register — Health and Human Services原文の発表を開く →

関連インサイト

ビジネスインサイト →